Clinical trials: Covid19- Coronavirus- Sars-cov-2
COVID-19, SARS-CoV 2
COVID-19 Survival - The COVIVA Study
The COVID-19 pandemic poses a major and imminent challenge for health care systems regarding patient triage and allocation of limited resources worldwide.
- Trial name
- COVIVA (NCT04366765)
- Where
- Switzerland
- Volunteers
- 1,325 people
- Sponsor
- University Hospital, Basel, Switzerland
SARS-CoV Infection, COVID-19
Malaysian COVID-19 Anosmia Study (Phase 1) - A Nationwide Multicentre Cross-Sectional Study
The Malaysian COVID-19 Anosmia Study is a nationwide multicentre observational study to investigate the prevalence and characteristics of olfactory and gustatory/taste disturbances in COVID-19 infection in Malaysia, and to…
- Conditions
- SARS-CoV Infection, COVID-19, Anosmia, Dysgeusia
- Trial name
- NCT04390165
- Testing
- Patient-Reported Online Questionnaire on Olfactory & Taste Disturbances
- Where
- 14 sites in Malaysia
- Volunteers
- 498 people
- Sponsor
- Hospital Sultanah Bahiyah
Long COVID
Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)
This study will use a prospective, open, single-arm design, in which a group of 100 patients with a diagnosis of prolonged COVID, previously selected according to inclusion and exclusion criteria, and who have undergone informed…
- Trial name
- NCT06637800
- Testing
- Seraph® 100 Microbind® Affinity Blood Filter (Seraph 100)
- Where
- Mexico
- Sponsor
- ExThera Medical Corporation
COVID-19
A Phase 2 Study of APX-115 in Hospitalized Patients With Confirmed Mild to Moderate COVID-19.
This phase 2 study is to assess the safety and tolerability of APX-115 active doses compared to placebo following multiple oral dosing in hospitalized patients with confirmed, mild to moderate, symptomatic COVID-19.
- Trial name
- NCT04880109
- Testing
- APX-115
- Where
- 6 sites in United States
- Volunteers
- 16 people
- Sponsor
- Aptabio Therapeutics, Inc.
Covid19
Artificial Intelligence - SARS-CoV-2 (COVID-19) Risk Evaluation
The management of COVID-19 patients in overwhelmed hospital facing the pandemic is a clinical challenge. The improvement of decision making may allow a better allocation of available resources and a better treatment of patients…
- Trial name
- AI-SCoRE (NCT04834934)
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- IRCCS San Raffaele
Sars-CoV2
Hydroxychloroquine or Diltiazem-Niclosamide for the Treatment of COVID-19
No optimal antiviral intervention has been yet validated to treat COVID-19 disease. Comorbidities, such as older age, obesity, diabetes, history of cardiovascular diseases are associated with poor prognosis.
- Trial name
- HYdILIC (NCT04372082)
- Testing
- Standard of care (SOC), Hydroxychloroquine, Association of diltiazem and niclosamide
- Sponsor
- University Hospital, Lille
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID
Convalescent Plasma in the Treatment of COVID 19
The purpose of this study is to collect blood from previously COVID-19 infected persons who have recovered and use it as a treatment for those who are currently sick with a severe or life-threatening COVID-19 infection.
- Conditions
- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), COVID, Coronavirus
- Trial name
- NCT04343261
- Testing
- Convalescent Plasma
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Trinity Health Of New England
COVID-19 Virus Infection
Clinical Study to Evaluate the Effect of Food Supplement in People Infected With Coronavirus
The purpose of the study is to assess safety and efficacy of Carnipure tartrate (L-Carnitine and L-tartaric acid - LCLT) supplementation for SARS-Cov-2 infection
- Trial name
- NCT05446961
- Testing
- LCLT : 68% elemental L-carnitine and 32 % Tartric acid
- Where
- Brazil
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- SENAI CIMATEC
Covid19
Outpatient Use of Ivermectin in COVID-19
Covid 19, a novel coronavirus, causes infection that, while mild to moderate in many people, can lead to severe disease in a significant portion.
- Trial name
- NCT04530474
- Testing
- Ivermectin Pill
- Where
- United States
- Sponsor
- Temple University
COVID-19; Immunity
Investigating Immune Escape by SARS-CoV-2 Variants
The purpose of this protocol is to investigate the ability of pre-existing immunity by natural infection or vaccination to prevent infections by emerging SARS-CoV-2 variants.
- Trial name
- NCT05171803
- Testing
- No intervention
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- University of California, Los Angeles
SARS-CoV Infection, Seroprevalence
Seroprevalence of SARS-CoV-2 in Unselected Surgical Patients: an Unicentric, Regional Study
The investigator analyzed the data of the patients admitted to the surgical department during the period 1St September - 10Th December 2020 to estimate the seroprevalence of SARS-CoV-2 infection in the setting of a non-dedicated…
- Conditions
- SARS-CoV Infection, Seroprevalence, Covid19
- Trial name
- COVID-19 (NCT04839913)
- Testing
- Antibodies testing
- Where
- Italy
- Volunteers
- 121 people
- Sponsor
- University of Cagliari
SARS-CoV-2 Infection, COVID19
Study to Evaluate Safety, Tolerability & Immunogenicity of BNT162b2 in Immunocompromised Participants ≥2 Years
This is a 4 dose study with 124 participants (7 adults ,117 children). Adults are considered to be participants 18 years of age or older. Participants are going to be enrolled based on conditions that make them immunocompromised.
- Trial name
- NCT04895982
- Testing
- BNT162b2
- Where
- 29 sites in United States, Brazil and 2 more
- Volunteers
- 124 people
- Sponsor
- BioNTech SE
Virus Diseases, Infection Viral
Proactive Protection With Azithromycin and hydroxyChloroquine in Hospitalized Patients With COVID-19
This study explores whether patients acutely hospitalized may have shorter hospitalization and fewer admittances at Intensive Care Units by treatment with azithromycin and hydroxychloroquine.
- Conditions
- Virus Diseases, Infection Viral, Corona Virus Infection
- Trial name
- ProPAC-COVID (NCT04322396)
- Testing
- Azithromycin, Hydroxychloroquine
- Where
- 8 sites in Denmark
- Volunteers
- 117 people
- Sponsor
- Chronic Obstructive Pulmonary Disease Trial Network, Denmark
COVID, Covid-19
Investigation of the Efficacy of CARDIO Softgels PLUS Best-standard-of-care in the Recovery of Patients With COVID-19
Corona virus disease 2019 (COVID-19) is caused by SARS-CoV-2, a plus-sense single-stranded RNA virus. After an incubation period, which typically lasts for 5-6 days, COVID-19 patients present with a mild illness that lasts for a…
- Trial name
- NCT04465513
- Testing
- Best Standard of Care + CARDIO, Best Standard of Care
- Where
- 8 sites in Brazil, Canada and 3 more
- Volunteers
- 14 people
- Sponsor
- Hofseth Biocare ASA
COVID-19 Infections in Cancer Patients
A Study of Risk Factors for the COVID-19 Virus Infection
The purpose of this study is to collect information that will help the reasearchers learn more about COVID-19 infections in cancer patients, and to find out about the effects of these infections on cancer treatment and outcomes.
- Trial name
- NCT04697927
- Testing
- Questionnaires
- Where
- 7 sites in United States
- Volunteers
- 389 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Covid19
Reactogenicity, Safety, and Immunogenicity of Covid-19 Vaccine Booster
Preliminary data suggest that inactivated vaccine-induced neutralizing antibodies against SARS-CoV-2 decrease at six months after vaccination.
- Trial name
- REFUERZO (NCT04992182)
- Testing
- Inactivated vaccine booster, mRNA vaccine booster, Viral vector vaccine booster
- Where
- 2 sites in Chile
- Volunteers
- 534 people, healthy volunteers welcome
- Sponsor
- Universidad del Desarrollo
COVID-19 Disease
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
To assess blood levels of vasoactive mediators that may regulate pulmonary endothelial permeability and contribute to multi-organ injury in patients with COVID-19 disease and to correlate the levels of these mediators with…
- Trial name
- NCT04587323
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Alabama at Birmingham
COVID-19, SARS-CoV-2
Molnupiravir and COVID-19 Mortality Reduction in the Omicron Era
This retrospective real-world target trial emulation uses complete Czech nationwide registry data to evaluate whether molnupiravir treatment is associated with lower COVID-19 mortality during the Omicron era.
- Trial name
- MOLCOVred (NCT07720596)
- Testing
- Molnupiravir
- Where
- Czechia
- Volunteers
- 1,795,570 people
- Sponsor
- Charles University, Czech Republic
Preterm Infant Development, COVID - 19
Development of Preterm Infants Born During the COVID-19 Pandemic
This study aims to evaluate differences in cognitive and psychomotor development among preterm infants (born before 34 weeks of gestation) delivered during the COVID-19 pandemic at Hospital de la Santa Creu i Sant Pau, compared…
- Trial name
- NCT07569523
- Testing
- Evaluation of cognitive and psychomotor development through the Bayley Scales Of Infant and Toddler Development and Wechsler Preschool and Primary Scale of Intelligence
- Volunteers
- 120 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Virus-HIV, Covid19
Impact of the Epidemic of COVID-19 Infection Among People Living With HIV (SARS-CoV-2)
The non-essential and non-urgent follow-up consultations of patients living with HIV were postponed or transformed into "teleconsultation" or exchanges of e-mails between practitioners and patients during COVID-19 epidemic.
- Trial name
- coVIHd-19 (NCT04581746)
- Testing
- questionnaire
- Where
- 3 sites in France
- Volunteers
- 1,800 people
- Sponsor
- Tourcoing Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.